Global Cardiology Academy

Welcome to Global
Cardiology Academy

Enhance your cardiology practice with CME and
tools focused on heart health management.

Steroidal vs Nonsteroidal MRAs: Implications for Heart Failure Care
Steroidal vs Nonsteroidal MRAs: Implications for Heart Failure Care
Heart Matters
Steroidal vs Nonsteroidal MRAs: Implications for Heart Failure Care
- Steve Jackson, PharmD
- Robert J. Mentz, MD, FHFSA, FACC
Making UACR a Routine Part of Diabetes Care
Making UACR a Routine Part of Diabetes Care
Heart Matters
Making UACR a Routine Part of Diabetes Care
- Steve Jackson, PharmD
- Robert J. Mentz, MD, FHFSA, FACC
Early Detection of ATTR-CM: Clinical Clues and Imaging Approaches
Early Detection of ATTR-CM: Clinical Clues and Imaging Approaches
On the Frontlines of ATTR-CM
Early Detection of ATTR-CM: Clinical Clues and Imaging Approaches
- Shelina Ramnarine, PhD
- Valmiki Maharaj, MD
CME/CE In-Person Event
Unblocking Clinical Inertia: The CMI Era in oHCM Care
May 09, 2026
Barcelona
0.75 credits
Athlete-Focused CPET: Interpreting Physiology Beyond Standardized Testing
Athlete-Focused CPET: Interpreting Physiology Beyond Standardized Testing
Heart Matters
Athlete-Focused CPET: Interpreting Physiology Beyond Standardized Testing
- Benjamin Levine, MD, FACC
Examining Barriers to Digital Healthcare in PAH
Examining Barriers to Digital Healthcare in PAH
Clinician's Roundtable
Examining Barriers to Digital Healthcare in PAH
- Daniel Lachant, D.O.
Advances in Sports Cardiology: Updates from ACC 2026
Advances in Sports Cardiology: Updates from ACC 2026
Heart Matters
Advances in Sports Cardiology: Updates from ACC 2026
- Jeffrey Hsu, MD, PhD
Hypertrophic Cardiomyopathy: Moving From Monitoring to Action in the Era of Myosin Inhibitors
Hypertrophic Cardiomyopathy: Moving From Monitoring to Action in the Era of Myosin Inhibitors
Cardiology
Hypertrophic Cardiomyopathy: Moving From Monitoring to Action in the Era of Myosin Inhibitors
- Joseph Rossano, MD

Programs

Evolocumab in Patients Without Significant Atherosclerosis and With Diabetes: A Cardiology Perspective on VESALIUS-CV
Evolocumab in Patients Without Significant Atherosclerosis and With Diabetes: A Cardiology Perspective on VESALIUS-CV
Cardiology
Evolocumab in Patients Without Significant Atherosclerosis and With Diabetes: A Cardiology Perspective on VESALIUS-CV
- Nicholas Marston, MD
Hypertrophic Cardiomyopathy: Overcoming Practical Barriers to Treatment in the Era of Myosin Inhibitors
Hypertrophic Cardiomyopathy: Overcoming Practical Barriers to Treatment in the Era of Myosin Inhibitors
Cardiology
Hypertrophic Cardiomyopathy: Overcoming Practical Barriers to Treatment in the Era of Myosin Inhibitors
- Florian Rader, MD
SCOUT-HCM: Mavacamten in Adolescents With Symptomatic Obstructive Hypertrophic Cardiomyopathy
SCOUT-HCM: Mavacamten in Adolescents With Symptomatic Obstructive Hypertrophic Cardiomyopathy
Cardiology
SCOUT-HCM: Mavacamten in Adolescents With Symptomatic Obstructive Hypertrophic Cardiomyopathy
- Joseph Rossano, MD
Counseling Patients on Disease Progression in ATTR-CM
Counseling Patients on Disease Progression in ATTR-CM
Heart Matters
Counseling Patients on Disease Progression in ATTR-CM
- Joban Vaishnav, MD
Supporting Patients With ATTR-CM: Preserving Function and Quality of Life
Supporting Patients With ATTR-CM: Preserving Function and Quality of Life
Heart Matters
Supporting Patients With ATTR-CM: Preserving Function and Quality of Life
- Joban Vaishnav, MD
Silencers and Stabilizers in ATTR-CM: Challenging Assumptions
Silencers and Stabilizers in ATTR-CM: Challenging Assumptions
Heart Matters
Silencers and Stabilizers in ATTR-CM: Challenging Assumptions
Fatty Acid Profiles May Be Linked to PAH Risk
Fatty Acid Profiles May Be Linked to PAH Risk
AudioAbstracts
Fatty Acid Profiles May Be Linked to PAH Risk
- Ryan Quigley
Reframing Palliative Care in PAH: Early Integration to Improve Outcomes
Reframing Palliative Care in PAH: Early Integration to Improve Outcomes
Clinician's Roundtable
Reframing Palliative Care in PAH: Early Integration to Improve Outcomes

Clinical Practice

Primary Care Takeaways From VESALIUS-CV: Evolocumab Efficacy in Patients Without Significant Atherosclerosis
Primary Care Takeaways From VESALIUS-CV: Evolocumab Efficacy in Patients Without Significant Atherosclerosis
Cardiology
Primary Care Takeaways From VESALIUS-CV: Evolocumab Efficacy in Patients Without Significant Atherosclerosis
- Javier Morales, MD, FACP, FACE
Understanding CPET for Athletes: Protocols and Pitfalls
Understanding CPET for Athletes: Protocols and Pitfalls
Heart Matters
Understanding CPET for Athletes: Protocols and Pitfalls
- Benjamin Levine, MD, FACC
Bringing PAH Care Home with Wearables and Telemedicine
Bringing PAH Care Home with Wearables and Telemedicine
Clinician's Roundtable
Bringing PAH Care Home with Wearables and Telemedicine
- Daniel Lachant, D.O.
Protecting Heart Health in Metastatic Breast Cancer
Protecting Heart Health in Metastatic Breast Cancer
Oncology and Hematology
Protecting Heart Health in Metastatic Breast Cancer
- Ryan Quigley
- Gregory Vidal, MD, PhD
Targeting Macrophages in Pulmonary Arterial Hypertension
Targeting Macrophages in Pulmonary Arterial Hypertension
Clinician's Roundtable
Targeting Macrophages in Pulmonary Arterial Hypertension
Heart Failure Hospitalization and Mortality in Cardiac Amyloidosis
Heart Failure Hospitalization and Mortality in Cardiac Amyloidosis
Heart Matters
Heart Failure Hospitalization and Mortality in Cardiac Amyloidosis
Beyond Steroidal MRAs: The Nonsteroidal MRA Lens in HF
Beyond Steroidal MRAs: The Nonsteroidal MRA Lens in HF
CME/CE
Beyond Steroidal MRAs: The Nonsteroidal MRA Lens in HF
0.25 credits
- Maria Pabon, MD
- Robert J. Mentz, MD, FHFSA, FACC
0.25 credits
FAI and the Future of Cardiac Risk Stratification
FAI and the Future of Cardiac Risk Stratification
Heart Matters
FAI and the Future of Cardiac Risk Stratification

CME

GDMT Is Working Fine, Why Add More Therapies? The Clinical Rationale for Layering Therapies in Patients with HFrEF
GDMT Is Working Fine, Why Add More Therapies? The Clinical Rationale for Layering Therapies in Patients with HFrEF
MinuteCE®
GDMT Is Working Fine, Why Add More Therapies? The Clinical Rationale for Layering Therapies in Patients with HFrEF
0.75 program credits
- Javed Butler, MD
- Carolyn S. P. Lam, MBBS, PhD
0.75 program credits
Missing the Window in Ambulatory Patients With HFrEF on GDMT: Strategies for CV Risk Reduction
Missing the Window in Ambulatory Patients With HFrEF on GDMT: Strategies for CV Risk Reduction
CME/CE
Missing the Window in Ambulatory Patients With HFrEF on GDMT: Strategies for CV Risk Reduction
0.25 credits
- Stephen J. Greene, MD, FACC, FHFSA
- Gianluigi Savarese, MD
0.25 credits
No Patient with CKD Left Behind! Emerging CKD Therapies in T1D
No Patient with CKD Left Behind! Emerging CKD Therapies in T1D
CME/CE
No Patient with CKD Left Behind! Emerging CKD Therapies in T1D
0.50 credits
- Richard E. Pratley, MD
- David Cherney, MD, PhD
- prof. Hiddo Heerspink
0.50 credits
Earlier Action, Lasting Impact: Closing the LDL-C Gap in Patients Without a Prior MACE
Earlier Action, Lasting Impact: Closing the LDL-C Gap in Patients Without a Prior MACE
CME/CE
Earlier Action, Lasting Impact: Closing the LDL-C Gap in Patients Without a Prior MACE
0.25 credits
- Erin Bohula, MD, DPhil
- Lawrence Leiter
0.25 credits
Engaging Your Patient: Shared Decision-Making in HF With LVEF ≥40%
Engaging Your Patient: Shared Decision-Making in HF With LVEF ≥40%
CME/CE
Engaging Your Patient: Shared Decision-Making in HF With LVEF ≥40%
0.25 credits
- Scott Solomon, MD
0.25 credits
The Hidden Threat: Transforming CKD Care Across the Diabetes Spectrum 
The Hidden Threat: Transforming CKD Care Across the Diabetes Spectrum 
CME/CE
The Hidden Threat: Transforming CKD Care Across the Diabetes Spectrum 
0.50 credits
- prof. Hiddo Heerspink
- Peter Rossing, MD, DMSc
- Paola Fioretto, MD
0.50 credits
New Insights in the Management of HCM: Exploring the Clinical Spectrum
New Insights in the Management of HCM: Exploring the Clinical Spectrum
CME/CE Broadcast Replay
New Insights in the Management of HCM: Exploring the Clinical Spectrum
0.50 credits
- Milind Y. Desai, MD, MBA
- Iacopo Olivotto, MD
- Elena Arbelo, MD, PhD
0.50 credits
Crossing Boundaries: CETP Inhibitors and the Next Frontier in Lipid Control
Crossing Boundaries: CETP Inhibitors and the Next Frontier in Lipid Control
CME/CE Broadcast Replay
Crossing Boundaries: CETP Inhibitors and the Next Frontier in Lipid Control
0.50 credits
- Prof. Ulrich Laufs
- Pam R. Taub, MD, FACC, FASPC
- Prof. John Kastelein, Chief Scientific Officer, NewAmsterdam Pharma
- Christie Ballantyne, MD
0.50 credits